Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Industries

    Local private firms to step up innovation

    By LIU ZHIHUA | China Daily | Updated: 2021-08-10 09:49
    Share
    Share - WeChat
    A researcher works at Clover Biopharmaceuticals' R&D center in Chengdu, Sichuan province. [Provided to China Daily]

    Clover received local government support to build a commercial manufacturing facility that completed construction in early 2020 in Huzhou, Zhejiang province.

    "Even though the company's drugs and vaccines were only in the preclinical stage then, their support allowed us to build a large facility that ended up being very important for our COVID vaccine program," Liang said.

    He also mentioned that the NMPA and its Center for Drug Evaluation have continued to expand their own capabilities, and the regulatory review timelines have been greatly shortened.

    The NMPA and CDE have also had a higher willingness to work together with biotech companies, and to have scientific and strategic discussions, he added.

    Shi Lichen, founder of Beijing Dingchen Consultancy, said Chinese pharmaceutical and biotech companies, among which many are non-State-owned, used to develop few self-developed original or innovative drugs. But things are changing mainly due to the improved regulatory environment, the stronger play of market mechanisms and booming venture capital/private equity investment.

    "China's medicine reforms in recent years are driving Chinese companies to focus more on new drug R&D and innovation to optimize product portfolios toward medium-to-high end returns, instead of simply profiting from the production and sales of low-quality generics," Shi said.

    Wei said most of the Chinese pharmaceutical enterprises focused on generics before regulatory reforms in 2015, but there are now a growing number of biotech companies developing innovative drugs.

    On the policy side, China joined the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, in 2017, and is actively implementing guidelines to encourage genuine indigenous innovations.

    In terms of industry practice, many Chinese pharmaceutical companies are establishing R&D centers and running clinical trials abroad. Cross-border deals have been active in the past few years, especially with a growing number of noticeable out-licensing deals, pointing to the future of "innovated in China", not just "made in China", he added.

    Industry insiders also said the booming VC/PE investment in China's pharmaceuticals sector has been further propelled by the pandemic and capital market reforms-such as the Science and Technology Innovation Board accepting listings from unprofitable companies and thus providing an exit mechanism for investors.

    According to global consultancy McKinsey & Co, there has been a strong rebound of healthcare VC/PE investment in 2020 after a decline in 2019. The total amount of VC/PE investment in the sector during the first half in 2020 had already exceeded that for the whole of 2019.

    Li Gang, partner of private investment bank CEC Capital, said accelerating reforms in China's capital market, including a registration-based system for IPOs and lower financial listing requirements, have provided investors clear exit strategies and thus have injected new momentum into healthcare investment.

    Liang said when he joined Clover in 2016, Chinese investors were still mainly looking at generics and biosimilars, while now there are many VC funds in China that want to support early-stage biotech companies, and some venture capital funds prefer to do Angel investing rounds, or even form companies from scratch.

    "The changing environment in the capital markets, with more funding for innovation, continues to support and foster continued growth of innovation in private Chinese pharmaceutical and biotech companies," Liang said.

    However, despite fast growth and increasing presence in the global industry arena, there is still a long way to go for China's non-State-owned pharmaceutical and biotech industry to become globally influential, experts said.

    Only 13 pharmaceutical and healthcare enterprises made the list of the top 500 Chinese private enterprises last year, which was released by the All-China Federation of Industry and Commerce.

    |<< Previous 1 2   
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    少妇无码AV无码专区线| 最近免费中文字幕mv电影| 亚洲欧美日韩国产中文| 精品欧洲av无码一区二区三区 | 精品爆乳一区二区三区无码av| 中文字幕乱偷无码AV先锋| 日韩国产成人无码av毛片| 最近高清中文在线国语字幕5| 成 人无码在线视频高清不卡| 一本色道久久HEZYO无码| 最近2019好看的中文字幕| 天堂无码在线观看| 精品无码一区二区三区爱欲| 日韩人妻无码一区二区三区| 色综合久久中文色婷婷| 中文日韩亚洲欧美字幕| 国产亚洲?V无码?V男人的天堂 | 中文字幕有码无码AV| 东京热无码av一区二区| 无码aⅴ精品一区二区三区浪潮 | 无码专区永久免费AV网站| 无码八A片人妻少妇久久| 精品久久久久中文字幕日本| 中文无码喷潮在线播放| 日韩精品无码永久免费网站| 久久精品国产亚洲AV无码偷窥 | 无码人妻一区二区三区在线| 亚洲国产中文v高清在线观看| 在线天堂中文在线资源网| 亚洲日韩v无码中文字幕| 中文字幕无码一区二区三区本日| 国产激情无码一区二区三区| 久久精品国产亚洲AV无码偷窥| 无码中文av有码中文a| 亚洲AV日韩AV永久无码绿巨人 | 亚洲VA中文字幕无码一二三区 | 精品无码国产污污污免费网站| 午夜亚洲AV日韩AV无码大全| 亚洲Av无码精品色午夜| 四虎成人精品无码| h无码动漫在线观看|